KPTI

Karyopharm Therapeutics Inc. KPTI

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,805 of 2,925

Why it scores 16Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$33.43M

Quarter to Jun 30

Net income

$-67.02M

Quarter to Jun 30

Operating margin

-67.4%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$206.77M total
RA CAPITAL MANAGEMENT, L.P.
$18.73M0.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$14.86M-15.8%
ACORN CAPITAL ADVISORS, LLC
$14.83M+427.4%
GOLDMAN SACHS GROUP INC
$13.92M+50.3%
BlackRock, Inc.
$13.86M+479.3%
VANGUARD CAPITAL MANAGEMENT LLC
$9.37M+29.6%
Catalio Capital Management, LP
$9.19M+4.8%
Avidity Partners Management LP
$9.03M+99.4%
T. Rowe Price Investment Management, Inc.
$7.68M-49.0%
TWO SIGMA INVESTMENTS, LP
$6.79M+359.7%
Kalehua Capital Management LLC
$6.70MNew
NEA Management Company, LLC
$5.64MNew
GEODE CAPITAL MANAGEMENT, LLC
$5.19M+157.7%
Ghisallo Capital Management LLC
$4.88MNew
Soleus Capital Management, L.P.
$4.30M0.0%
UBS Group AG
$3.45M+82.2%
STATE STREET CORP
$3.18M+303.7%
Affinity Asset Advisors, LLC
$3.05M-37.5%
Brevan Howard Capital Management LP
$3.03M+45.9%
MILLENNIUM MANAGEMENT LLC
$2.99M-27.3%
Boxer Capital Management, LLC
$2.96M0.0%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
$2.93M0.0%
ACADIAN ASSET MANAGEMENT LLC
$2.92M+20.1%
SILVERARC CAPITAL MANAGEMENT, LLC
$2.91MNew
Eversept Partners, LP
$2.70M0.0%
See all 97 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KPTI

Earnings Per Share

13fpro.ai/company/KPTI

Loading ratio trend…

KPTI key financials by period

Reported revenue, net income and operating margin by fiscal year, from Karyopharm Therapeutics Inc.'s annual filings on SEC EDGAR.

Karyopharm Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$146.1M$-196.0M-62.1%
FY 2024$145.2M$-76.4M-82.2%
FY 2023$146.0M$-143.1M-88.7%
FY 2022$157.1M$-165.3M-90.5%
FY 2021$209.8M$-124.1M-46.8%
FY 2020$108.1M$-196.3M-159.0%
Source: KPTI filings on SEC EDGAR →

Companies similar to KPTI

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

KPTI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Karyopharm Therapeutics Inc. (KPTI): stock profile, AI score and financials

Karyopharm Therapeutics Inc. (KPTI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KPTI at 16.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,805 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.3) and institutional flow (4.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Karyopharm Therapeutics Inc. reports quarterly revenue of $33.4M, net income of $-67.0M, an operating margin of -67.4%. Top institutional holders of KPTI by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., ACORN CAPITAL ADVISORS, based on the most recent SEC filings. KPTI trades on the Nasdaq exchange and files with the SEC under CIK 1503802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KPTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Karyopharm Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1503802 →